Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
BRIEF-Ionis And Partner Announce Enrollment Completion Of Global Phase 3 Generation Hd1 Study For Huntington's Disease
11:18am, Monday, 20'th Apr 2020
Ionis Pharmaceuticals Inc:
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
11:05am, Monday, 20'th Apr 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for
Needham Believes Seattle Genetics (SGEN) Won't Stop Here
09:54am, Monday, 20'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Seattle Genetics (SGEN), with a price target of $157.00. The company's
Needham Believes Seattle Genetics (NASDAQ: SGEN) Won’t Stop Here
09:54am, Monday, 20'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Seattle Genetics (SGEN – Research Report),
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares Purchased by Gateway Investment Advisers LLC
09:41am, Thursday, 16'th Apr 2020
Gateway Investment Advisers LLC increased its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 96.3% during the 1st quarter, according to its most recent filing with the Securities and Ex
Ionis Pharmaceuticals to hold a webinar IONS
01:06pm, Wednesday, 15'th Apr 2020
Ionis Pharmaceuticals to hold a webinar IONS
IFM Investors Pty Ltd Sells 333 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
10:58am, Wednesday, 15'th Apr 2020
IFM Investors Pty Ltd lowered its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Excha
With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer
08:00am, Wednesday, 15'th Apr 2020
Some of the targets in cancer research are visible and well known, but they’re hard to hit with new drugs all the same. PIC Therapeutics is developing
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Cytokinetics (CYTK), with a price target of $24.00. The company's shares
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Cytokinetics (
CYTK
–
Research Report
), with a price target of
$24.00
. The company’s shares closed last Tuesday at
n-Lorem Foundation receives $500,000 donation for providing experimental antisense medicines to treat patients with ultra-rare diseasesPR NewswireCARLSBAD, Calif., April 14, 2020CARLSBAD, Calif.
Needham Maintains Their Buy Rating on Athersys (ATHX)
02:19pm, Monday, 13'th Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Athersys (ATHX) today and set a price target of $6.00. The company's shares closed last Monday at
Needham Maintains Their Buy Rating on Athersys (ATHX)
02:19pm, Monday, 13'th Apr 2020
Needham analyst Chad Messer maintained a Buy rating on Athersys (ATHX – Research Report) today and set a price target
Needham Keeps a Buy Rating on NextCure (NXTC)
02:15pm, Monday, 13'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC) today and set a price target of $72.00. The company's shares closed last Monday at
Needham Keeps a Buy Rating on NextCure (NXTC)
02:15pm, Monday, 13'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on NextCure (NXTC – Research Report) today and set a price target
